

THC BIOMED INTL LTD. P.O. Box 20033 Towne Centre Kelowna, B.C. V1Y 9H2 www.thcbiomed.com

THC Expands Facilities and Completes Phase 1 Expansion

THC.CSE THCBF - OTC TFHC.F

Vancouver, British Columbia – (November 3, 2017) THC BioMed Intl Ltd. (CSE: THC), ("THC" or the "Company") is pleased to announce that it has completed the acquisition of two additional units to add to its existing facilities in Kelowna, British Columbia.

The additional units add 4,000 square feet to THC's facilities and are to be used for production space. This increases THC's footprint to 20,000 square feet.

The total purchase price of the two units was \$485,000 in an arm's-length transaction. \$185,000 was paid in cash and a \$300,000 mortgage was obtained by the company. An agent's fee of \$10,000 per unit, for a total of \$20,000, was paid to Amazing Green Environmental Products Inc.

THC also announces that it has completed Phase 1 of its expansion plan through the construction of four (4) new grow rooms. Pending Health Canada's approval, THC will be able to begin production in those four new rooms.

Phase 2 of THC's expansion schedule is ahead of schedule. Phase 2 includes the construction of a storage vault and twelve (12) production rooms. The storage vault has been completed and the rest of the construction for Phase 2 is expected to be completed in December 2017.

Phase 3, which includes the construction of 14 new production rooms, is expected to be completed in February 2018.

About THC

THC's vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

President and CEO:

John Miller THC Biomed Intl Ltd. T: 1-844-THCMEDS

E: info@thcbiomed.com

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that: (a) the new units and grow rooms will be used for production; (b) the rest of the construction for Phase 2 is will be completed in December 2017; (c) Phase 3 will be completed in February 2018; (d) THC's vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence; (d) as the medical marijuana industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis; and (d) THC will be in the forefront of this rapidly growing industry.

THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.